Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160563 | PMC |
http://dx.doi.org/10.2337/ds21-0025 | DOI Listing |
Expert Opin Drug Saf
January 2024
Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: There is limited evidence on the safety of sodium-glucose co-transporter-2 inhibitor (SGLT2i) use in the real world of China. We conducted this two-center, retrospective study to assess the incidence rate and risk factors of Dapagliflozin-associated DK/DKA among patients with type 2 diabetes mellitus (T2DM) in China.
Research Design And Methods: Patients with T2DM treated with Dapagliflozin in Shanghai General Hospital were included in this retrospective analysis.
Diabetes Res Clin Pract
February 2023
Department of Cardiology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China. Electronic address:
Objective: To investigate the risk factors of dapagliflozin-associated diabetic ketosis/ketoacidosis (DK/DKA) in patients with type 2 diabetes mellitus (T2DM).
Research Design And Methods: A case-control study was conducted in a general hospital in China from 2018 to 2021. T2DM patients who developed DK/DKA after dapagliflozin treatment were identified.
Diabetes Spectr
September 2021
Department of Pharmacy Practice, Southwestern Oklahoma State University College of Pharmacy, Weatherford, OK.
Nephrology (Carlton)
February 2018
Department of Nephrology, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Linkou, Taiwan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!